This inventor holds 1 USPTO granted patent. Top assignee: Centro De Immunologia Molecular. Active years: 1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999
Title: Gilda Nurez Gandolf: Innovator in Vaccine Development
Introduction
Gilda Nurez Gandolf is a prominent inventor based in Habana, Cuba. She has made significant contributions to the field of immunology, particularly in the development of vaccine compositions. Her innovative work focuses on utilizing autologous epidermal growth factor (EGF) to combat EGF-dependent tumors and diseases.
Latest Patents
Gilda holds 1 patent for her invention titled "Vaccine composition comprising autologous epidermal growth factor." This invention provides novel uses of EGF and vaccine compositions that include EGF. Specifically, it employs autologous EGF, or its fragments and derivatives, as an active immunization against the proliferation of EGF-dependent tumors and other related diseases. The invention also suggests coupling autologous EGF to carrier proteins, such as tetanus toxoid or cholera toxin B chain, and typically includes an adjuvant like aluminum hydroxide.
Career Highlights
Gilda Nurez Gandolf is affiliated with the Centro de Inmunología Molecular, where she continues her research and development efforts. Her work has been instrumental in advancing vaccine technology and improving therapeutic options for patients suffering from EGF-dependent conditions.
Collaborations
Gilda collaborates with notable colleagues, including Augustin Bienvenido Davila and Gisela Gonzalez Marinello. Their combined expertise contributes to the innovative research environment at the Centro de Inmunología Molecular.
Conclusion
Gilda Nurez Gandolf's contributions to vaccine development highlight her role as a key innovator in the field of immunology. Her work not only advances scientific knowledge but also has the potential to improve patient outcomes in the fight against EGF-dependent diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile